

Nivolumab in the treatment of non-squamous non-small cell lung cancer in 2nd and higher line in real clinical practice: the Czech registry TULUNG

Špaček J., Zemanová M., Zemanová P., Kultán J., Fischer O., Havel L., Drosslerová M., Krejčí D., Opálka P., Hrnčiarik M., Svatoň M., Pešek M., Jakubíková L., Skříčková J., Koubková L., Bílek O., Brožová L., Hejduk K., Šťastný M., Petruželka L

Introduction: The treatment of non-small cell lung cancer (NSCLC) has undergone enormous changes in the last 5 years. The introduction of modern approaches using treatment with checkpoint inhibitors has meant a fundamental change, and at least 5 drugs targeting PD-1 or PD-L1 are currently approved in the EU. All of these drugs have been approved through registration studies, however, it appears that patients in the studies may not accurately reflect the profile of patients encountered by the physician in real clinical practice.

Aim of the work: This work aims to discuss and analyze preliminary results of treatment with anti-PD1 antibody nivolumab in non-squamous NSCLC in Czech clinical practice within the data collection for the VILP registry.

Results: More than 200 male-dominated patients (54 %) were analyzed. Despite the relatively short follow-up period, these data confirm the efficacy of nivolumab in real clinical practice. Survival data for individual groups of patients by age, by number of metastases and number of organs affected, and progression-free survival by incidence of adverse events will be presented.

Discussion and Conclusions: The analysis of treatment data from real clinical practice is important not only to show whether treatment outcomes meet the expectations that emerged from clinical trials, but it is also important to obtain additional information.

References: 1. Wierzbicka et al. JHPOR. 2015; 1: 15–33. 2. Carroll et al. Drug and Alcohol Dependence 54 (1999) 171–177. 3. Kim H-S et al. J Korean Med Sci. 2018 Aug 20; 33 (34): e213. 4. Webster and Smith. Clin Ther. 2019 Feb; 41 (2): 336–349. 5. Misra and Agarwal. Rheumatol Int. 2019 Mar; 39 (3): 403–416. 6. Wong SE et al. Clin Genitourin Cancer. <https://doi.org/10.1016/j.clgc.2017.08.019>.